On Wednesday, Impetus Drugs (CPRX) got a move up to its Relative Strength (RS) Rating, from 78 to 81.
While searching for the best stocks to purchase and watch, one component to observe intently is relative cost strength.
IBD’s exclusive RS Rating recognizes specialized execution by showing how a stock’s cost activity throughout the course of recent weeks has what it takes against that of different stocks in our data set.
History shows that the best stocks regularly have a RS Rating more than 80 as they start their greatest runs.